Mark C. Markowski, Ph.D.
Affiliations: | 2009 | Tumor Biology | Georgetown University, Washington, DC |
Area:
Cell BiologyGoogle:
"Mark Markowski"Parents
Sign in to add mentor| Edward P. Gelmann | grad student | 2009 | Georgetown | |
| (Inflammatory cytokines induce ubiquitination and loss of the prostate suppressor protein NKX3.1.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Chen J, Zheng Q, Hicks JL, et al. (2023) MYC-driven increases in mitochondrial DNA copy number occur early and persist throughout prostatic cancer progression. Jci Insight |
| Chen J, Zheng Q, Hicks JL, et al. (2023) MYC-driven increases in mitochondrial DNA copy number occur early and persist throughout prostatic cancer progression. Biorxiv : the Preprint Server For Biology |
| Mandl A, Markowski MC, Carducci MA, et al. (2023) Role of bromodomain and extraterminal (BET) proteins in prostate cancer. Expert Opinion On Investigational Drugs. 1-16 |
| Sena LA, Wang T, Wang H, et al. (2022) Updated analyses for RESTORE cohort C: A trial of bipolar androgen therapy for patients with newly castration-resistant prostate cancer. European Journal of Cancer (Oxford, England : 1990). 181: 23-25 |
| Tran PT, Lowe K, Tsai HL, et al. (2022) Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2201662 |
| Sena LA, Kumar R, Sanin DE, et al. (2022) Prostate cancer androgen receptor activity dictates efficacy of bipolar androgen therapy through MYC. The Journal of Clinical Investigation |
| Markowski MC, Wang H, De Marzo AM, et al. (2022) Clinical Efficacy of Bipolar Androgen Therapy in Men with Metastatic Castration-Resistant Prostate Cancer and Combined Tumor-Suppressor Loss. European Urology Open Science. 41: 112-115 |
| Markowski MC, Tutrone R, Pieczonka C, et al. (2022) A Phase 1b/2 Study of Sabizabulin, a Novel Oral Cytoskeleton Disruptor, in Men With Metastatic Castration-Resistant Prostate Cancer with Progression on an Androgen Receptor Targeting Agent. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research |
| Denmeade S, Antonarakis ES, Markowski MC. (2022) Bipolar androgen therapy (BAT): A patient's guide. The Prostate |
| Werner RA, Habacha B, Lütje S, et al. (2022) High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with F-DCFPyL. Molecular Imaging. 2022: 7056983 |